Abstract: Objective To evaluate the efficacy and safety of Nab-paclitaxel（Nab-P） on patients with advanced pancreatic carcinoma who failed to gemcitabine first-line therapy. Methods Patients with advanced pancreatic carcinoma who have failed to first-line therapy from May 2012 to May 2015 were analyzed retrospectively. All the patients received Nab-P-based monotherapy or combination regimens（Nab-P 110 mg／m2 iv， d1，d8， every 3 weeks） as second or more line treatments. The efficacy and safety were evaluated by RECIST 1.1 and NCI-CTC 4.0 criteria. Median time to disease progression（TTP） and overall survival（OS） were analyzed by Kaplan-Meier method. Results Thirteen patients failured to gemcitabinebased regimen were enrolled and 9 of them were evaluatable. The median age was 56.1 years， and the average treatment cycle was 2.27. The disease control rate（DCR） was 55.6％， including 2 cases of PR， 3 cases of SD and 4 cases of PD. The number of patients with elevated baseline CA19-9 had＞50％ decline was 4（44.4％）. The median TTP was 30 months（95％CI： 2.4-4.2 months） and the median OS was 14.2 months（95％CI： 2.8-25.6 months）.The 3-month and 6-month survival rate was 88.9％ and 77.8％， respectively. The major treatment-related side effects including leucopenia， neutropenia， nausea， vomiting， fatigue and etc. were mainly in grade 1-2. Conclusion Nab-paclitaxe is effective and tolerable in Chinese advanced pancreatic carcinoma patients who have progressed on gemcitabine first-line therapy.